Therapy Detail

Therapy Name M7824
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
M7824 MSB0011359C Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 TGFBR2 Antibody 2 M7824 is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03631706 Phase II M7824 Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03524170 Phase I M7824 RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Recruiting
NCT03554473 Phase Ib/II M7824 + Topotecan M7824 + Temozolomide M7824 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Recruiting
NCT03436563 Phase Ib/II M7824 M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer Recruiting
NCT03707587 Phase II M7824 M7824 in People With Recurrent Respiratory Papillomatosis Recruiting
NCT03833661 Phase II M7824 M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) Not yet recruiting
NCT03427411 Phase II M7824 Phase II Trial of M7824 in Subjects With HPV Positive Malignancies Recruiting
NCT02517398 Phase I M7824 MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors Recruiting
NCT03840902 Phase II Paclitaxel + Carboplatin M7824 Cisplatin + Pembrolizumab Cisplatin + Etoposide Durvalumab Cisplatin + Etoposide + M7824 Carboplatin + M7824 + Paclitaxel Cisplatin + M7824 + Pemetrexed M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Not yet recruiting
NCT03620201 Phase I M7824 M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC) Recruiting